The ESMO 2016 guidelines suggest the use of new-generation TKIs, according to the results of mutational analysis of BCR-ABL1 transcripts in patients with relapsed Ph+ ALL (13). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.